Expertise in
1
conditions

Dr. Sonja D. Bartolome

Intensive Care Medicine
Victory Medical Center Fort Worth LP
600 S Main St, 
Fort Worth, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
1
conditions
Victory Medical Center Fort Worth LP
600 S Main St, 
Fort Worth, TX 

Overview

Sonja Bartolome is an Intensive Care Medicine provider practicing medicine in Fort Worth, Texas.

Dr. Bartolome is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Systemic Sclerosis (SSc), Liver Failure, Pulmonary Fibrosis, Heart Failure with Preserved Ejection Fraction (HFpEF), and Angioplasty.

She is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 10 clinical trials. Dr. Bartolome is currently accepting new patients.

Specialties

Intensive Care Medicine

Licenses

Critical Care Medicine in TX

Hospital Affiliations

UT Of Texas Southwestern University Hospital - William P. Clements Jr.

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Victory Medical Center Fort Worth LP
600 S Main St, Fort Worth, TX 76104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

42 Total Publications

Corrigendum to 'The landscape of referrals for lung transplantation in pulmonary arterial hypertension: A report from the Pulmonary Hypertension Association Registry'[J Heart Lung Transplant, 45 (2026) 125-136].
Corrigendum to 'The landscape of referrals for lung transplantation in pulmonary arterial hypertension: A report from the Pulmonary Hypertension Association Registry'[J Heart Lung Transplant, 45 (2026) 125-136].
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: March 26, 2026
Similar Doctors
Expertise in
1
conditions
Dr. Benjamin H. Levi
Intensive Care Medicine
Expertise in
1
conditions
Dr. Benjamin H. Levi
Intensive Care Medicine
Referral may be required
Before you request

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (29.0 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Benjamin Levi is an Intensive Care Medicine provider practicing medicine in Dallas, Texas. Dr. Levi is highly rated in 1 condition, according to our data. His clinical expertise encompasses Kienbock's Disease, Tenotomy, and Osteotomy. Dr. Levi is currently accepting new patients.

Expertise in
14
conditions
Dr. Samer H. Fahoum
Intensive Care Medicine | Pulmonary Medicine
Expertise in
14
conditions
Dr. Samer H. Fahoum
Intensive Care Medicine | Pulmonary Medicine
Referral may be required
Before you request

Texas Pulmonary & Critical Care Consultants

1201 Fairmount Ave, 
Fort Worth, TX 
 (1.0 miles away)
817-335-5288
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Samer Fahoum is an Intensive Care Medicine specialist and a Pulmonary Medicine provider practicing medicine in Fort Worth, Texas. Dr. Fahoum is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Pleurisy, Pleural Effusion, Lung Metastases, and Chronic Obstructive Pulmonary Disease (COPD). Dr. Fahoum is currently accepting new patients.

Expertise in
4
conditions
Dr. Michael L. Stanchina
Intensive Care Medicine | Sleep Medicine
Expertise in
4
conditions
Dr. Michael L. Stanchina
Intensive Care Medicine | Sleep Medicine
Referral may be required
Before you request

Access TeleCare- Tele ICU

1717 Main St, Ste 5850, 
Dallas, TX 
 (30.9 miles away)
866-483-9690
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Stanchina is an Intensive Care Medicine specialist and a Sleep Medicine provider practicing medicine in Dallas, Texas. Dr. Stanchina is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Obstructive Sleep Apnea, Emphysema, Central Sleep Apnea, and Lung Nodules. Dr. Stanchina is board certified in American Board Of Internal Medicine, Pulmonary Disease, Sleep Medicine, Internal Medicine, and Critical Care Medicine. Dr. Stanchina is currently accepting new patients.

Frequently Asked Questions about Dr. Sonja D. Bartolome

How do I make an appointment with Dr. Sonja D. Bartolome?

You can book an appointment with Dr. Sonja D. Bartolome by calling their office at 817-882-2420. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sonja D. Bartolome a top-rated expert for Systemic Sclerosis (SSc)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sonja D. Bartolome is classified as an Advanced expert for Systemic Sclerosis (SSc), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sonja D. Bartolome specialize in?

While Dr. Sonja D. Bartolome is a Intensive Care Medicine, they have specific expertise in Systemic Sclerosis (SSc), Liver Failure, and Pulmonary Fibrosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Sonja D. Bartolome participate in research or clinical trials?

Yes. Dr. Sonja D. Bartolome has published 42 articles and abstracts on conditions like Systemic Sclerosis (SSc). You can view a list of Dr. Sonja D. Bartolome's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sonja D. Bartolome accept my insurance?

Dr. Sonja D. Bartolome accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 817-882-2420 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bartolome's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile